PFAS, the synthetic chemicals found in nonstick coatings, waterproof fabrics, and firefighting foam, appear to push the immune system toward attacking the body’s own tissues. The connection is not a single clean pathway but rather a web of disruptions: PFAS alter how immune cells communicate, shift the balance between different types of white blood cells, and seem to both suppress certain immune defenses and amplify others. The result is a growing body of evidence tying these chemicals to conditions like ulcerative colitis, rheumatoid arthritis, thyroid disease, and potentially multiple sclerosis. What makes the picture especially unsettling is that PFAS do not simply weaken or strengthen immunity. They appear to scramble it.
The Immune System Running Two Programs at Once
The most counterintuitive thing about PFAS immunotoxicity is that these chemicals can suppress parts of the immune system while simultaneously ramping up others. A review exploring the mechanisms behind this found that PFAS modulate key signaling pathways inside cells, including NF-κB (a master switch for inflammation) and a family of nuclear receptors called PPARs that regulate immune cell behavior.1PubMed Central. Consideration of pathways for immunotoxicity of per- and polyfluoroalkyl substances (PFAS) The practical consequence is that the immune system can end up in a confused state: weaker at fighting infections and responding to vaccines, yet more prone to inflammatory overreaction against the body’s own tissues.
This dual disruption helps explain why researchers studying PFAS exposure see what look like contradictory results. In some studies, exposed populations have lower antibody responses to childhood vaccinations. In others, the same chemicals are associated with higher rates of autoimmune disease. These are not contradictions. They reflect the same underlying problem: immune regulation going haywire in multiple directions at once.
What Happens to T Cells and B Cells
Two branches of the immune system show clear signs of PFAS-driven disruption. On the T cell side, research on people exposed to perfluorinated compounds found that PFAS exposure is associated with increased levels of activated T helper memory cells, with profiles skewed toward Th2, Th17, and regulatory T cell patterns.2PubMed Central. Immune cell profiles associated with human exposure to perfluorinated compounds (PFAS) suggest changes in natural killer, T helper, and T cytotoxic cell subpopulations Th17 cells are particularly relevant to autoimmune disease because they drive inflammation in conditions like rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. When the immune system over-produces Th17 cells or fails to keep them in check, the result is chronic inflammation directed at the body’s own tissues.
A separate line of research identified PFAS binding to inflammatory cytokine targets including IL-1β, TNF, and IL-6, along with a proposed IL-17/Th17 signaling axis through which these chemicals may trigger autoimmune responses.3PubMed. Per- and polyfluoroalkyl substances trigger autoimmune diseases through inflammatory cytokines-IL-17/Th17 signaling axis In plain terms, PFAS molecules appear to physically latch onto the same proteins that control inflammation, potentially amplifying immune responses that would otherwise stay in proportion.
On the B cell side, a study of Czech adults examined how multiple PFAS exposures affected gene activity in blood cells. The researchers found that PFAS exposure was associated with downregulation of genes involved in B cell development, particularly the later stages where B cells mature in germinal centers and differentiate into antibody-producing plasma cells.4PubMed Central. Altered Transcriptome Response in PBMCs of Czech Adults Linked to Multiple PFAS Exposure: B Cell Development as a Target of PFAS Immunotoxicity Disrupted B cell maturation could mean the body produces the wrong kinds of antibodies or fails to properly distinguish self from non-self, both hallmarks of autoimmune disease.
Neutrophils Under Pressure
The immune cells most people never hear about may also be affected. Neutrophils are the first responders of the innate immune system, and one of their key weapons is the “respiratory burst,” a rapid release of reactive oxygen species that kills invading microbes. Research on both legacy PFAS and newer replacement compounds like GenX found that these chemicals suppress the neutrophil respiratory burst in human cell models and in zebrafish larvae, with GenX also suppressing the burst in primary human neutrophils.5Taylor & Francis Online (Journal of Immunotoxicology). Legacy and emerging per- and polyfluoroalkyl substances suppress the neutrophil respiratory burst This matters for autoimmunity because when innate immune function is suppressed, the body sometimes compensates by over-activating other arms of immunity, setting the stage for misdirected attacks.
Specific Autoimmune Conditions Linked to PFAS
The epidemiological evidence is strongest for a handful of conditions where large exposed populations have been studied. Each case offers a different window into how PFAS-related immune disruption plays out in the body.
Ulcerative Colitis
The clearest dose-response relationship comes from the Mid-Ohio Valley, where tens of thousands of residents were exposed to PFOA through contaminated drinking water from a chemical plant. A study of that population found a striking pattern: ulcerative colitis incidence rose steadily with increasing PFOA exposure. Compared to the lowest exposure group, people in the highest quartile had roughly triple the rate of new ulcerative colitis diagnoses, and the trend across all four exposure levels was highly consistent.6PubMed Central. Ulcerative Colitis and Perfluorooctanoic Acid (PFOA) in a Highly Exposed Population of Community Residents and Workers in the Mid-Ohio Valley Ulcerative colitis involves the immune system attacking the lining of the colon, and the dose-response gradient strengthens the case that PFAS exposure is not merely coincidental.
Rheumatoid Arthritis
Two separate studies point toward a connection between PFAS and rheumatoid arthritis. One found that serum concentrations of all detected PFAS were higher in RA patients than in healthy controls.7PubMed Central. The influences of perfluoroalkyl substances on the rheumatoid arthritis clinic Another went further, examining whether PFAS levels correlated with the specific immune markers that drive RA. That study found positive correlations between PFOA and PFOS concentrations and several key markers: anti-cyclic citrullinated peptide antibodies, immunoglobulin G, rheumatoid factors, and C-reactive protein, a broad measure of inflammation.8PubMed. Per-/polyfluoroalkyl substance concentrations in human serum and their associations with immune markers of rheumatoid arthritis The researchers noted it was the first study to report significant associations between multiple PFAS and changes in these specific immune markers, suggesting PFAS may increase RA risk in adults.
Thyroid Disease
The thyroid is a common target of autoimmune attack, and PFAS appear to disrupt thyroid hormone systems. A review of in vitro, animal, and epidemiological data concluded that PFAS may disrupt thyroid hormone function in humans, with possible negative effects on pregnancy outcomes and child development, though the overall findings remain mixed and sometimes contradictory.9PubMed Central. Thyroid Disrupting Effects of Old and New Generation PFAS The inconsistency in thyroid studies is worth noting because it may reflect the complexity of how different PFAS compounds, at different doses and life stages, interact with an organ that is exquisitely sensitive to hormonal disruption.
Multiple Sclerosis
Newer research has begun exploring links between PFAS and multiple sclerosis. An exploratory analysis comparing MS patients with healthy controls in U.S. cohorts found significant interactions between MS status and PFOA for several steroid metabolites, along with tentative enrichment of neuronal membrane pathways among PFAS-correlated genes.10PubMed Central. Associations between perfluoroalkyl substances and multiple sclerosis in U.S. cohorts compared with NMOSD, MOGAD, and healthy controls This is early-stage research and the findings are described as exploratory, but the biological plausibility is strong given what is known about Th17 cell involvement in MS and the tendency of PFAS to skew toward that profile.
The Vaccine Response Puzzle
Reduced antibody responses to childhood vaccines have become one of the most-cited pieces of evidence for PFAS immunotoxicity, influential enough that both the U.S. Environmental Protection Agency and the European Food Safety Authority used this endpoint to set safety thresholds. A study looking at children ages four to eight found that prenatal PFAS exposure was associated with lower vaccine titers for measles and mumps: each log-unit increase in one PFAS compound roughly doubled the odds of having a low measles titer, and a different compound showed a similar pattern for mumps.11PubMed Central. Prenatal Exposure to Poly- and Perfluoroalkyl Substances (2009–2014) and Vaccine Antibody Titers of Measles, Mumps, Rubella, and Varicella in Children Four to Eight Years Old from the Healthy Start Cohort
However, the picture in adults is far less clear. A study of adults with historically elevated PFAS exposure through drinking water who received COVID-19 vaccination found no measurable impact of serum PFAS concentrations on antibody response. Results across multiple analytical approaches consistently showed that PFAS had little or no effect on vaccine-generated antibodies in this adult population.12Journal of Exposure Science & Environmental Epidemiology. Immune response to COVID-19 vaccination in a population with a history of elevated exposure to per- and polyfluoroalkyl substances (PFAS) through drinking water The discrepancy between findings in children and adults matters. It suggests that the developing immune system may be more vulnerable to PFAS disruption, a pattern consistent with broader research on how prenatal and early-life exposures shape immune programming for decades.
Why Early Exposure May Matter Most
Research on prenatal PFAS exposure adds a worrying dimension. A study examining cord blood from newborns who later developed immune-mediated diseases found that more associations between PFAS exposures and altered metabolic profiles appeared in cases than in controls.13Journal of Exposure Science & Environmental Epidemiology. Prenatal exposure to environmental contaminants and cord serum metabolite profiles in future immune-mediated diseases The implication is that PFAS exposure before birth may set metabolic and immune trajectories that only become apparent years later as autoimmune conditions emerge. This aligns with the broader concept that the immune system is most sensitive to environmental programming during fetal development, when its fundamental self-versus-non-self distinctions are being established.
Replacement PFAS Are Not Necessarily Safer
As legacy compounds like PFOA and PFOS have been phased out under regulatory pressure, manufacturers have introduced shorter-chain and structurally modified replacements. The assumption that these newer chemicals would be less toxic to the immune system is not holding up well under scrutiny.
Lab studies directly comparing legacy and replacement PFAS on human immune cells have found that the newer compounds still alter immune function, just in different and sometimes unpredictable ways. One study found that while PFOS suppressed inflammatory cytokine release from monocytes, the replacement compound GenX increased markers associated with a suppressive immune phenotype often linked to tumor-associated macrophages. Other replacement compounds triggered simultaneous inflammatory and anti-inflammatory responses, an uncoordinated pattern that does not occur in healthy immune function.14PubMed. Per- and polyfluoroalkyl substances (PFAS) alter immune responses from THP-1 human monocytes
A study testing six PFAS analogues on human blood cells found that several enhanced T cell proliferation while a partially overlapping group suppressed cytokine secretion, showing the same paradoxical pattern of simultaneous immune stimulation and suppression seen with legacy compounds.15PubMed. A human PBMC-based new approach method reveals PFAS-driven T-cell proliferation and immune dysregulation Another study noted that T cells appear to be more sensitive to PFAS than monocytes, suggesting that adaptive immunity, the branch most directly involved in autoimmune disease, may be particularly vulnerable.16PubMed. In vitro cytotoxicity of six per- and polyfluoroalkyl substances (PFAS) in human immune cell lines The upshot is that switching from one PFAS to another has not eliminated the immune disruption problem. It may have simply shuffled the deck.
How PFAS Linger in the Body
Part of what makes PFAS dangerous to the immune system is their persistence. These molecules bind tightly to proteins in the blood and liver. Research measuring how PFAS bind to serum albumin, one of the most abundant blood proteins, found binding affinities in a range that helps explain why these chemicals resist elimination and stay circulating where immune cells encounter them constantly.17PubMed. Binding of per- and polyfluoroalkyl substances with liver and serum proteins in rats: implications for physiologically based pharmacokinetic modelling Without active intervention, the half-life of some PFAS in the human body can stretch to seven years or more, meaning that every exposure builds on the last.
This persistence creates a scenario unlike most other environmental exposures. With something like pesticide residue or a medication, the body clears the substance within hours or days. With PFAS, the immune system is living in a bath of these chemicals year after year, and any immune disruption they cause is not a one-time insult but an ongoing pressure.
When Exposures Combine
People are rarely exposed to a single PFAS in isolation, and they are also exposed to other environmental pollutants simultaneously. Research testing PFAS alongside microplastics on human cell lines found synergistic effects, meaning the combination was worse than either one alone. The synergy showed up primarily in kidney and liver cells as increased oxidative stress, elevated antioxidant gene expression, and activation of DNA repair pathways. The severity depended on both the dose and the ratio of PFAS to microplastics.18Environmental Pollution. Synergistic toxicity of PFAS and microplastic mixtures across five human cell lines While this study focused on liver and kidney cells rather than immune cells directly, oxidative stress and cellular damage in these organs can trigger systemic immune responses that feed into autoimmune pathways.
Can You Lower Your PFAS Levels?
Because PFAS leave the body so slowly on their own, researchers have explored medical interventions to speed elimination. A randomized clinical trial of 285 Australian firefighters, a population with high occupational exposure, found that both blood and plasma donations significantly lowered PFAS levels compared to observation alone. Plasma donation was the most effective, reducing serum PFOS by about 2.9 ng/mL compared to 1.1 ng/mL for whole blood donation.19PubMed Central. Effect of Plasma and Blood Donations on Levels of Perfluoroalkyl and Polyfluoroalkyl Substances in Firefighters in Australia A Randomized Clinical Trial
A separate study of firefighters using cholestyramine, a bile-acid binding drug originally designed to lower cholesterol, found even more dramatic results. The treatment group showed an annual decrease in serum PFOS of about 41%, with an estimated half-life of 1.2 years, compared to 12% annual decrease and a half-life of 7.3 years in the observation group.20PubMed. Changes in serum perfluorooctane sulfonic acid and perfluorohexane sulfonic acid concentrations in firefighters accessing a voluntary perfluoroalkyl and polyfluoroalkyl substances reduction treatment program These are still small studies in highly exposed populations, and no clinical guidelines yet recommend either approach for the general public. But the fact that PFAS elimination can be accelerated raises the possibility that reducing body burden could, in theory, reduce ongoing immune disruption.
Where Regulators Draw the Line
The immune effects of PFAS have directly shaped drinking water regulations. The U.S. EPA dramatically lowered its interim health advisories for PFOA and PFOS in drinking water, from a previous level of 70 parts per trillion down to 0.04 to 0.2 parts per trillion, with suppressed vaccine response in children serving as a key basis for the revision.21PubMed. Critical endpoints of PFOA and PFOS exposure for regulatory risk assessment in drinking water: Parameter choices impacting estimates of safe exposure levels
Whether those limits are strict enough remains debated. An early benchmark dose analysis based on children’s immune data concluded that existing drinking water limits at the time appeared to be several hundred-fold too high to protect against immunotoxic effects.22PubMed Central. Immunotoxicity of perfluorinated alkylates: calculation of benchmark doses based on serum concentrations in children A more recent analysis comparing U.S. and European approaches found that the European Food Safety Authority’s proposed tolerable exposure limit appeared too high, while the EPA’s more stringent proposal was in better alignment with what the immune data actually supported.23PubMed Central. Benchmark dose calculations for PFAS exposure based on two data sets on immunotoxic effects The trend across regulatory agencies has been toward ever-lower permissible levels, driven largely by the immune evidence. What is notable is that autoimmune outcomes like ulcerative colitis and rheumatoid arthritis were not the primary basis for these thresholds; vaccine suppression in children was. If regulators eventually incorporate the autoimmune disease data, the thresholds could shift again.
What Makes This Hard to Study
Autoimmune diseases are difficult to link to any single environmental factor because they typically develop over years, involve genetic susceptibility, and are influenced by dozens of other exposures and lifestyle factors. PFAS research faces additional challenges. Nearly everyone in industrialized countries has measurable PFAS in their blood, which means there is no truly unexposed comparison group. People are exposed to mixtures of different PFAS compounds, not just one, making it hard to isolate the effects of individual chemicals. And the same compound can behave differently in a developing fetus, a child, and an adult, complicating any attempt to draw universal conclusions.
The strongest evidence so far comes from communities with unusually high exposures, like the Mid-Ohio Valley PFOA contamination or occupationally exposed firefighters. These populations provide something closer to a dose-response gradient. But they also represent extreme cases, and it remains an open question how much of the autoimmune risk translates to people with the lower, background-level exposures that characterize most of the population. The biological mechanisms are plausible at lower concentrations, the T cell skewing, the B cell gene suppression, and the cytokine pathway disruption all occur in lab settings at levels that overlap with real-world human exposure. But moving from plausible mechanism to proven cause in a general population is a gap that epidemiology has not yet fully closed.